Literature DB >> 8195164

A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides.

H Itabe1, E Takeshima, H Iwasaki, J Kimura, Y Yoshida, T Imanaka, T Takano.   

Abstract

In this study we have used homogenates of human atheromatous plaque as immunogen to establish a murine monoclonal antibody which recognizes oxidized low density lipoprotein (LDL). This monoclonal antibody, FOH1a/DLH3, reacted with oxidized LDL, but enzyme-linked immunosorbent assay showed that it had no reaction with native, acetylated, or malonaldehyde-treated LDL. The antibody cross-reacted with oxidized high density lipoprotein, suggesting that specific sequences of the apolipoprotein B are not essential for antigen recognition by the antibody. Immunohistochemical analysis of thin paraffin sections from human coronary arteries showed that foam cells derived from macrophages in atherosclerotic lesions were heavily stained by this antibody. Several other structures in the lesions, including swollen collagen fibers, cellular debris in necrotic cores, and endothelial cells, were moderately stained. The epitope of this antibody was characterized by a model antigen-generating system using ferrous ion-induced peroxidation of lipids. When the total lipid fraction extracted from LDL was treated with the ferrous ion-induced peroxidation system, the reaction mixture was recognized by the antibody. Antigenic product(s) was produced only when phosphatidylcholine (PC) was treated with the ferrous ion-induced peroxidation, other lipids failed to react to the antibody. To investigate the possible formation of a complex of antigenic product with a polypeptide, a synthetic peptide and a rabbit antiserum against the peptide were used. Reaction mixture of ferrous ion-induced peroxidation of PC in the presence of the peptide was added to a microtiter well precoated with the monoclonal antibody FOH1a/DLH3. After washing, the peptide remaining in the well was detected with rabbit antiserum against the peptide, whereas no reactivity was observed when peptide alone was added to the well. Binding of the antigenic complex to the precoated monoclonal antibody was competed by oxidized PC produced in the absence of any polypeptide. We conclude that oxidized phospholipid product(s) is the epitope of the monoclonal antibody and that the oxidized phospholipid forms complexes with polypeptides. The antigenic materials are detected in foam cells in atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195164

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

2.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 3.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

4.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

5.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.

Authors:  Naoko Sawada; Takashi Obama; Shinji Koba; Takashi Takaki; Sanju Iwamoto; Toshihiro Aiuchi; Rina Kato; Masaki Kikuchi; Yuji Hamazaki; Hiroyuki Itabe
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

Review 7.  Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Authors:  Luis R Lopez; Kazuko Kobayashi; Yukana Matsunami; Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 8.  Oxidative modification of LDL: its pathological role in atherosclerosis.

Authors:  Hiroyuki Itabe
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

9.  Immunohistochemical detection of 13(R)-hydroxyoctadecadienoic acid in atherosclerotic plaques of human carotid arteries using a novel specific antibody.

Authors:  Noriyuki Shibata; Sono Toi; Takahiro Shibata; Koji Uchida; Hiroyuki Itabe; Tatsuo Sawada; Takakazu Kawamata; Yoshikazu Okada; Shinichiro Uchiyama; Makio Kobayashi
Journal:  Acta Histochem Cytochem       Date:  2009-12-22       Impact factor: 1.938

10.  Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration.

Authors:  Mihoko Suzuki; Motohiro Kamei; Hiroyuki Itabe; Kazuhito Yoneda; Hajime Bando; Noriaki Kume; Yasuo Tano
Journal:  Mol Vis       Date:  2007-05-23       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.